Cabiralizumab
- Generic Name
- Cabiralizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1613144-80-1
- Unique Ingredient Identifier
- 5FJL6W0640
- Background
Cabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03927105
- Locations
- 🇺🇸
Unviersity of Wisconsin, Madison, Wisconsin, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).
Phase 2
Suspended
- Conditions
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Hitendra Patel
- Target Recruit Count
- 40
- Registration Number
- NCT03697564
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 42
- Registration Number
- NCT03502330
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 60
- Registration Number
- NCT03431948
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath